ETV4-Mediated PD-L1 Upregulation Promotes Immune Evasion and Predicts Poor Immunotherapy Response in Melanoma
Oncology Research · 2026 · 34 (1) · 1-10
DOI: 10.32604/or.2025.070180 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Research, 2026. Verfasst von Tao Zhu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China. Hauptthemen laut MEDLINE: Melanoma, B7-H1 Antigen, Adenovirus E1A Proteins, Tumor Escape. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China.
- Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, 310014, China.
Zitieren
APA
Zhu, T., Wei, T., Yang, M., Xu, J., Jiang, H., He, W., Zheng, J., & Dai, H. (2026). ETV4-Mediated PD-L1 Upregulation Promotes Immune Evasion and Predicts Poor Immunotherapy Response in Melanoma. Oncology Research, 34(1), 1-10. https://doi.org/10.32604/or.2025.070180
Vancouver
Zhu T, Wei T, Yang M, Xu J, Jiang H, He W, et al. ETV4-Mediated PD-L1 Upregulation Promotes Immune Evasion and Predicts Poor Immunotherapy Response in Melanoma. Oncology Research. 2026;34(1):1-10. doi:10.32604/or.2025.070180
BibTeX
@article{Zhu2026,
author = {Zhu, Tao and Wei, Taofeng and Yang, Mingdong and Xu, Junjun and Jiang, Huifang and He, Wei and Zheng, Juyan and Dai, Haibin},
title = {ETV4-Mediated PD-L1 Upregulation Promotes Immune Evasion and Predicts Poor Immunotherapy Response in Melanoma},
journal = {Oncology Research},
year = {2026},
volume = {34},
number = {1},
pages = {1--10},
doi = {10.32604/or.2025.070180}
}
EUVIMED